JP2001504104A - アルツハイマー病の治療法 - Google Patents
アルツハイマー病の治療法Info
- Publication number
- JP2001504104A JP2001504104A JP52167498A JP52167498A JP2001504104A JP 2001504104 A JP2001504104 A JP 2001504104A JP 52167498 A JP52167498 A JP 52167498A JP 52167498 A JP52167498 A JP 52167498A JP 2001504104 A JP2001504104 A JP 2001504104A
- Authority
- JP
- Japan
- Prior art keywords
- folate
- vitamin
- folic acid
- mixture
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アルツハイマー病を治療し、または虚血および/または神経変性に至る微 小血管事態を抑制する方法であって、ホモシステインの少なくとも適度に高い血 中濃度の減少を引き起こすか、または脳の血管系または神経細胞に対するホモシ ステインの少なくとも適度に高い血中濃度の毒性作用を和らげる薬物の治療上有 効量を、かかる処置を必要とする患者に投与することから成る方法。 2.アルツハイマー病を治療する方法であって、ホモシステインの少なくとも 適度に高い血中濃度の減少を引き起こすか、または脳の血管系または神経細胞に 対するホモシステインの少なくとも適度に高い血中濃度の毒性作用を和らげる薬 物の治療上有効量を、かかる治療を必要とする患者に投与することから成る方法 。 3.患者が、少なくとも適度に高い血中濃度のホモシステインと少なくとも適 度に低い血中濃度の葉酸塩およびビタミンB12を有している請求の範囲2に記載 の方法。 4.投与される薬物が、葉酸もしくは葉酸塩あるいはその誘導体またはベタイ ンもしくはビタミンB6またはこれらの2種以上の混合物である請求の範囲2に 記載の方法。 5.薬物が、葉酸(プテロイルモノグルタメート)、1種以上のホリルポリグ ルタメート、葉酸のプテリン成分のまたはホリルポリグルタメートのピラジン環 が還元されて、ジヒドロ葉酸塩またはテトラヒドロ葉酸塩を付与する化合物、あ るいはN−5位またはN−10位に種々の酸化水準の1つの炭素構成単位を有す る上記化合物全ての誘導体、またはこれらの2種以上の混合物である請求の範囲 4に記載の方法。 6.薬物が、葉酸、ジヒドロ葉酸塩、テトラヒドロ葉酸塩、5−メチルテトラ ヒドロ葉酸塩、5,10−メチレンテトラヒドロ葉酸塩、5,10−メテニルテ トラヒドロ葉酸塩、5,10−ホルムイミノテトラヒドロ葉酸塩、5−ホルミル テトラヒドロ葉酸塩(ロイコボリン)、10−ホルミルテトラヒドロ葉酸塩、ま たはこれらの2種以上の混合物である請求の範囲5に記載の方法。 7.ビタミンB12を投与する工程をさらに包含する請求の範囲3に記載の方 法。 8.使用する薬物が、酸化窒素ドナー、NEP/ACE抑制剤、ACE抑制剤 もしくはアンギオテンシンIIアンタゴニスト、葉酸、葉酸塩あるいはその誘導体 またはベタインもしくはビタミンB6、またはこれらの2種以上の混合物である 請求の範囲2に記載の方法。 9.アンギオテンシン変換酵素抑制剤が、カプトプリル、ホシノプリル、リシ ノプリル、エナラプリル、ラミプリル、キナプリル、フエンチアプリル、ベナゼ プリルまたはモエキシプリルで、アンギオテンシンIIアンタゴニストがアーベサ ータンまたはロサータンである請求の範囲8に記載の方法。 10.酸化窒素ドナーが、イソソルビドモノニトレートもしくはイソソルビドジ ニトレートまたはニトログリセリンである請求の範囲8に記載の方法。 11.投与される薬物が、ACE抑制剤もしくはアンギオテンシンIIアンタゴニ ストと、葉酸、葉酸塩あるいはその誘導体の組合せである請求の範囲8に記載の 方法。 12.薬物が、(a)カプトプリル、ホシノプリルまたはアーベサータンと、 (b)葉酸、葉酸塩あるいはその誘導体の組合せである請求の範囲11に記載の 方法。 13.葉酸、葉酸塩あるいはその誘導体またはベタインもしくはビタミンB6を 、約0.1〜100mg範囲内の1日用量で投与する請求の範囲2に記載の方法。 14.ビタミンB12を約0.001〜10mg範囲内の1日用量で投与する請求の 範囲7に記載の方法。 15.コリンエステラーゼ抑制剤、ムスカリン様レセプタ作用薬、β−アミロイ ド産生の抑制剤、神経原線維変化形成の抑制剤またはこれらの2種以上の混合物 である、アルツハイマー病を治療する薬物の投与をさらに包含する請求の範囲2 に記載の方法。 16.閉塞性血管病を治療する方法であって、ホモシステインの少なくとも適度 に高い血中濃度の減少を引き起こすか、または脳の血管系または神経細胞に対す るホモシステインの少なくとも適度に高い血中濃度の毒性作用を和らげる薬物の 治療上有効量を、かかる治療を必要とする患者に投与することから成る方法。 17.閉塞性血管病が、閉塞性大脳血管病または閉塞性末梢血管病である請求の 範囲16に記載の方法。 18.一過性脳虚血発作(TIA)、発作、間欠跛行、血管痴呆、多梗塞痴呆、 老人性徴候痴呆、早老性痴呆またはビンスワンガー病を治療する請求の範囲16 に記載の方法。 19.使用する薬物が、葉酸もしくは葉酸塩あるいはその誘導体、ベタインもし くはビタミンB6、またはそれらの2種以上の混合物、あるいはこれらと酸化窒 素ドナー、ACE抑制剤、アンギオテンシンIIアンタゴニストまたはNEP/A CE抑制剤の1種以上、および必要に応じてビタミンB12との組合せである請求 の範囲16に記載の方法。 20.薬物が、葉酸(プテロイルモノグルタメート)、1種以上のホリルポリグ ルタメート、葉酸のプテリン成分のまたはホリルポリグルタメートのビラジン環 が還元されて、ジヒドロ葉酸塩またはテトラヒドロ葉酸塩を付与する化合物、あ るいはN−5位またはN−10位に種々の酸化水準の1つの炭素構成単位を有す る上記化合物全ての誘導体、またはこれらの2種以上の混合物である請求の範囲 19に記載の方法。 21.薬物が、葉酸、ジヒドロ葉酸塩、テトラヒドロ葉酸塩、5−メチルテトラ ヒドロ葉酸塩、5,10−メチレンテトラヒドロ葉酸塩、5,10−メテニルテ トラヒドロ葉酸塩、5,10−ホルムイミノテトラヒドロ葉酸塩、5−ホルミル テトラヒドロ葉酸塩(ロイコボリン)、10−ホルミルテトラヒドロ葉酸塩、ま たはこれらの2種以上の混合物である請求の範囲19に記載の方法。 22.ビタミンB12を投与する工程をさらに包含する請求の範囲19に記載の方 法。 23.アンギオテンシン変換酵素抑制剤が、カプトプリル、ホシノプリル、リシ ノプリル、エナラプリル、ラミプリル、キナプリル、フエンチアプリル、ベナゼ プリルまたはモエキシプリルで、アンギオテンシンIIアンタゴニストがアーベサ ータンまたはロサータンである請求の範囲19に記載の方法。 24.酸化窒素ドナーが、イソソルビドモノニトレートもしくはイソソルビドジ ニトレートまたはニトログリセリンである請求の範囲19に記載の方法。 25.(1)葉酸もしくは葉酸塩またはその誘導体;および (2)ビタミンB12 の組合せから成る医薬組成物。 26.酸化窒素ドナー、ACE抑制剤もしくはアンギオテンシンIIアンタゴニス ト、あるいはNEP/ACE抑制剤、またはこれらの2種以上の混合物、または コリンエステラーゼ抑制剤、ムスカリン様レセプタ作用薬、β−アミロイド産生 の抑制剤、神経原線維変化形成の抑制剤またはこれらの2種以上の混合物をさら に包含する請求の範囲25に記栽の医薬組成物。 27.(1)葉酸もしくは葉酸塩あるいはその誘導体、ベタインもしくはビタミ ンB6またはこれらの2種以上の混合物;および (2)ビタミンB12または (3)酸化窒素ドナー、AEC抑制剤もしくはアンギオテンシンIIアンタゴニ スト、あるいはNEP/ACE抑制剤、またはこれらの2種以上の混合物の少な くとも1種 の組合せから成る医薬組成物。 28.葉酸または葉酸塩とホシノプリルまたはカプトプリルから成る請求の範囲 27に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3064296P | 1996-11-06 | 1996-11-06 | |
US60/030,642 | 1996-11-06 | ||
PCT/US1997/020021 WO1998019690A1 (en) | 1996-11-06 | 1997-11-04 | Method for treating alzheimer's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001504104A true JP2001504104A (ja) | 2001-03-27 |
JP2001504104A5 JP2001504104A5 (ja) | 2005-07-14 |
Family
ID=21855203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52167498A Ceased JP2001504104A (ja) | 1996-11-06 | 1997-11-04 | アルツハイマー病の治療法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US6008221A (ja) |
EP (1) | EP0951293A4 (ja) |
JP (1) | JP2001504104A (ja) |
AU (1) | AU719290B2 (ja) |
CA (1) | CA2270780A1 (ja) |
WO (1) | WO1998019690A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011736A1 (ja) * | 2003-07-30 | 2005-02-10 | Tohoku Techno Arch Co., Ltd. | アルツハイマー病の予防および/または治療剤 |
WO2009041700A1 (ja) * | 2007-09-28 | 2009-04-02 | Kobayashi Pharmaceutical Co., Ltd. | 医薬組成物 |
JP2009173640A (ja) * | 2007-12-27 | 2009-08-06 | Suntory Holdings Ltd | ホモシステイン低下用組成物 |
JP2010535752A (ja) * | 2007-08-08 | 2010-11-25 | ザ・ユニバーシティ・オブ・マンチェスター | 水頭症の治療および予防 |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566065B1 (en) * | 1994-05-26 | 2003-05-20 | Mcgill University | Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene |
GB9410620D0 (en) | 1994-05-26 | 1994-07-13 | Univ Mcgill | cDNA for human mehylenetetrahydrofolate reductase |
US20050137191A1 (en) * | 1996-06-04 | 2005-06-23 | Thatcher Gregory R. | Nitrate esters and their use for mitigating cellular damage |
US6310052B1 (en) * | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
US6274564B1 (en) | 1996-09-18 | 2001-08-14 | William J. Sarill | Compositions of cobalamin and related corrinoids, and uses thereof |
CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
KR100572080B1 (ko) | 1997-10-17 | 2006-04-17 | 유로진 리미티드 | 레닌-안지오텐신계 억제제의 용도 |
JPH11217330A (ja) * | 1998-01-30 | 1999-08-10 | Sumitomo Pharmaceut Co Ltd | 神経栄養因子分泌促進剤 |
MXPA01000973A (es) * | 1998-08-03 | 2002-06-04 | Epigenesis Pharmaceuticals Inc | Un nuevo agente analgesico antiinflamatorio y de cicatrizacion de heridas. |
ES2194513T3 (es) * | 1998-10-30 | 2003-11-16 | Merck Patent Gmbh | Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas. |
WO2000025764A2 (en) * | 1998-10-30 | 2000-05-11 | Merck Patent Gmbh | Compositions for the treatment and prevention of cardiovascular diseases |
DE19913528A1 (de) * | 1998-12-21 | 2000-06-29 | Sanol Arznei Schwarz Gmbh | Neue Verwendung von Moexipril |
EP1139913A4 (en) * | 1999-01-05 | 2002-09-11 | Univ East Carolina | COMPOSITION AND FORMULATIONS AND THEIR USE AS NOCICEPTIVES, ANTI-ANXIOLYTICS AND ANABOLISERS |
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
BE1012495A3 (fr) * | 1999-03-02 | 2000-11-07 | Messadek Jallal | La glycine-betaine pour son usage antithrombotique. |
WO2000057879A1 (en) * | 1999-03-26 | 2000-10-05 | Barry Reisberg | Treatment of brain changes with myelin protective agents |
WO2001000047A1 (en) * | 1999-06-29 | 2001-01-04 | The New Zealand Milk Institute Limited | Prophylactic dietary supplement based on milk |
JP2003507418A (ja) * | 1999-08-24 | 2003-02-25 | メディキュア インターナショナル インコーポレイテッド | 心血管疾患とその関連疾患の治療 |
AU1243101A (en) * | 1999-10-28 | 2001-05-08 | Cary Pharmaceuticals Inc. | High dose folic acid for the treatment of hyperhomocysteinemia |
DE10004651A1 (de) * | 2000-02-03 | 2001-08-16 | Jutta Dierkes | Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen |
US6586414B2 (en) | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
DK1272220T4 (en) * | 2000-04-10 | 2016-11-28 | Nicholas John Wald | Cardiovascular disease prevention formulation |
US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
DE10022510A1 (de) * | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
US20090017069A1 (en) | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
WO2002083151A2 (en) * | 2000-12-14 | 2002-10-24 | Tufts University | Compositions and methods for treating an arthritic condition |
US6537992B2 (en) * | 2001-01-05 | 2003-03-25 | John D. Parker | Regulation of organic nitrate tolerance |
BR0101088A (pt) * | 2001-03-19 | 2003-03-18 | Biolab Sanus Farmaceutica Ltda | Processo de isolamento e purificação de peptìdeos inibidores das vasopeptidases, com especificidade para o sìtio carboxìlico da enzima conversora da angiotensina, secretados pelas glândulas do veneno de serpentes (bpps), particularmente bothrops jararaca, ou produzidos endogenamente (evasins) possuindo ação vasodilatadora e anti-hipertensiva; processo de determinação da sequência de amido-ácidos dos peptìdios inibidores secretados pela glândula de veneno de serpentes (bpps) ou endógenos (evasins); processo de determinação da sequência de aminoácidos dos bpps por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca. processo de determinação da sequência de aminoácidos dos evasins por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca, processo de amplificação do cdna a partir das bibliotecas de cdna de pâncreas e/ou cérebro de serpentes, especificamente bothrops jararaca; processo de sìntese em fase sólida de peptìdeos inibidores das vasopeptidases com ação vasodilatadora e anti-hipertensiva, peptìdeos inibidores das vasopeptidases com ação anti-hipertensiva; utilização dos peptìdeos inibidores das vaso peptidases com ação vasodilatadora e anti-hipertensiva na obtenção de composições farmacêuticas; processo de determinação da atividade inibitória sobre as vasopeptidases e de atividade biológica sobre músculo liso, sistema cardiovascular e microcirculatório. |
EP1381373B1 (en) * | 2001-04-25 | 2006-06-14 | Cobalz Limited | Medical compositions for use in the treatment or prevention of a functional vitamin b12 deficienfcy |
WO2003000372A2 (en) * | 2001-06-25 | 2003-01-03 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
US20030127386A1 (en) * | 2001-06-25 | 2003-07-10 | Bomberger David C. | Hollow fiber contactor systems for removal of lipids from fluids |
CA2464561A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US7319145B2 (en) * | 2001-12-03 | 2008-01-15 | Rima Rozen | Methylenetetrahydrofolate reductase inhibitors and use thereof |
US20060160896A1 (en) * | 2002-02-04 | 2006-07-20 | Jallal Messadek | Therapeutic treatment |
BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
CH696628A5 (de) * | 2002-02-26 | 2007-08-31 | Eprova Ag | Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der |
US20040162292A1 (en) * | 2002-12-03 | 2004-08-19 | Evenstad Kenneth L. | Multivitamin formulations for promoting healthy collagen, and methods of their use |
EP1615632B1 (fr) * | 2003-04-17 | 2006-12-06 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
DK2368565T3 (en) | 2003-07-03 | 2015-09-28 | Hdl Therapeutics Inc | Enrichment of pre-beta lipoproteins, high density |
US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
US6951658B1 (en) * | 2003-07-08 | 2005-10-04 | Pearson Research & Development Limited | Emu-based compositions for mental well-being and method of use |
US8173618B2 (en) * | 2003-07-25 | 2012-05-08 | University Of Massachusetts | Formulations for reducing neuronal degeneration |
US20050032740A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin compositions for the treatment and prevention of vascular disease and dementia |
US20050032741A1 (en) * | 2003-08-06 | 2005-02-10 | Balaji Venkataraman | Vitamin Compositions |
PL1750862T3 (pl) | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
EP1645276A1 (en) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Treatment of neurodegenerative disorders |
WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
EP2242489A1 (en) | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
CN101180073A (zh) | 2005-04-27 | 2008-05-14 | 贾拉尔·梅萨德克 | 胰岛素组合 |
US20070010492A1 (en) * | 2005-07-11 | 2007-01-11 | Generale Robert J | Composition and method for reducing homocysteine caused by drugs containing methyl compounds |
US20080193385A1 (en) * | 2007-02-08 | 2008-08-14 | Todd Maibach | Compositions and methods for treating neuropathy |
US8178133B2 (en) | 2007-03-22 | 2012-05-15 | Magceutics, Inc. | Magnesium compositions and uses thereof |
US8597640B2 (en) * | 2007-10-31 | 2013-12-03 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
EP2588198A1 (en) | 2010-07-01 | 2013-05-08 | Isis Innovation Limited | Treatment of cognitive disorders |
WO2013025607A1 (en) * | 2011-08-12 | 2013-02-21 | The Florida State University Research Foundation Inc. | Methods of treating amyloidoses with vitamin b12 and test for detecting amyloid-beta peptides |
US20150065449A1 (en) | 2011-08-12 | 2015-03-05 | Florida State University Research Foundation, Inc. | Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG |
CN103386130A (zh) * | 2013-06-27 | 2013-11-13 | 深圳奥萨医药有限公司 | Ace抑制剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物及用途 |
US10661099B2 (en) * | 2015-06-16 | 2020-05-26 | Eugene R. Moore | Treatment of alzheimer's disease |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
US10201577B2 (en) | 2017-02-14 | 2019-02-12 | Keyview Labs, Inc. | Compositions and methods for enhancing working and long-term memory support using new combination of ginkgo biloba and panax ginseng and associated components |
JP2021504003A (ja) | 2017-11-22 | 2021-02-15 | エイチディーエル セラピューティクス インコーポレイテッドHdl Therapeutics, Inc. | 血漿処理システムの流体回路をプライミングするシステムおよび方法 |
CA3087207A1 (en) | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11547688B2 (en) * | 2019-08-22 | 2023-01-10 | Nodari Rizun | Amino acid compositions and methods of manufacturing the compositions |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
EP0581856B1 (en) * | 1991-04-19 | 1999-07-14 | The Children's Medical Center Corporation | Method of preventing nmda receptor complex-mediated neuronal damage |
CA2078019C (en) * | 1991-09-13 | 2002-08-27 | Siegbert Heinrich Bissbort | Substance or composition and uses thereof |
CA2105177A1 (en) * | 1992-09-14 | 1994-03-15 | Willem Jacob Serfontein | Pharmaceutical preparations for lowering homocysteine levels |
DE4326675C2 (de) * | 1993-08-09 | 1996-12-12 | Puetter Medice Chem Pharm | Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Vorbeugung von Nervendegenerationserkrankungen und Altersdementia |
US5738873A (en) * | 1996-09-27 | 1998-04-14 | Herman Bleiweiss | Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia |
-
1997
- 1997-10-28 US US08/959,035 patent/US6008221A/en not_active Expired - Lifetime
- 1997-11-04 EP EP97947335A patent/EP0951293A4/en not_active Ceased
- 1997-11-04 AU AU52442/98A patent/AU719290B2/en not_active Ceased
- 1997-11-04 JP JP52167498A patent/JP2001504104A/ja not_active Ceased
- 1997-11-04 WO PCT/US1997/020021 patent/WO1998019690A1/en not_active Application Discontinuation
- 1997-11-04 CA CA002270780A patent/CA2270780A1/en not_active Abandoned
-
1999
- 1999-11-08 US US09/435,804 patent/US6127370A/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011736A1 (ja) * | 2003-07-30 | 2005-02-10 | Tohoku Techno Arch Co., Ltd. | アルツハイマー病の予防および/または治療剤 |
JP2010535752A (ja) * | 2007-08-08 | 2010-11-25 | ザ・ユニバーシティ・オブ・マンチェスター | 水頭症の治療および予防 |
WO2009041700A1 (ja) * | 2007-09-28 | 2009-04-02 | Kobayashi Pharmaceutical Co., Ltd. | 医薬組成物 |
JP2009173640A (ja) * | 2007-12-27 | 2009-08-06 | Suntory Holdings Ltd | ホモシステイン低下用組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO1998019690A1 (en) | 1998-05-14 |
US6008221A (en) | 1999-12-28 |
US6127370A (en) | 2000-10-03 |
EP0951293A1 (en) | 1999-10-27 |
AU719290B2 (en) | 2000-05-04 |
CA2270780A1 (en) | 1998-05-14 |
AU5244298A (en) | 1998-05-29 |
EP0951293A4 (en) | 2002-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001504104A (ja) | アルツハイマー病の治療法 | |
US20180177874A1 (en) | Methods of Treating Metabolic Syndrome Using Dopamine Receptor Agonists | |
Kang et al. | Cross-talk between cytokines and renin–angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-κB | |
EP2282778B1 (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis | |
Matsumoto et al. | Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats | |
JP5710131B2 (ja) | sAPPα分泌を増強させる及びブリオスタチン型化合物を用いて認知を改善させるための手段としてのPKC活性化 | |
JP6151013B2 (ja) | 細胞成長、シナプスリモデリング及び長期記憶の固定を刺激する方法 | |
EP2189537B1 (en) | Detection and treatment of schizophrenia | |
US8334262B2 (en) | Cognitive function | |
US8003631B2 (en) | Composition and method for the treatment of tauopathies | |
WO2014090990A1 (en) | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease | |
JP2006518765A (ja) | アデノシンa1受容体アンタゴニストを使って疾患を処置する方法 | |
RU2194508C2 (ru) | Комбинированный препарат для лечения слабоумия | |
EP3010500A1 (en) | Methods for identifying neuroprotective pkc activators | |
JP4890759B2 (ja) | sAPPα分泌を増強させる及びブリオスタチン型化合物を用いて認知を改善させるための手段としてのPKC活性化 | |
Wan et al. | Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD | |
US20120010264A1 (en) | Novel medicament for treating cognitive impairment | |
US20100331363A1 (en) | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor | |
AU2013263800B2 (en) | Methods of treating metabolic syndrome using dopamine receptor agonists | |
Mori et al. | Construction of a screening system for lipid-derived radical inhibitors and validation of hit compounds to target retinal and cerebrovascular diseases | |
AU2022380947A1 (en) | Treatment of a selective population of patients having dementia with lewy bodies | |
WO2008138968A2 (en) | Dosage form comprising 10-[(3s)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine, provided in a form suitable for oral administration of a daily dose of 1 mg to 3 mg |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080311 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080611 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080718 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081028 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081216 |